4
Shared Docs
4
Same-Page
4 / 4
Mentions
imers. The discovery is critical, explains Dr. Bin Zhang, a co-lead author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. Because we can now "evaluate drugs that impact the TREM2-TYROBP pathway as potential therapies... and design more specific compounds that target th
atical model, a unified map of not only the prevailing genes present in late Alzheimer's but the various pathways that they trigger. One such gene, TYROBP, not typically connected to Alzheimer's but linked to brain inflammation, was shown to interact with TREM2, a gene recently connected to Alzheimer's
zheimer's. The discovery is critical, Dr. Bin Zhang explained, a co-author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. "We can now evaluate drugs that impact the TFtEM2- TYROBP pathway as potential therapies... and design more specific compounds that target these key
a co-author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. "We can now evaluate drugs that impact the TFtEM2- TYROBP pathway as potential therapies... and design more specific compounds that target these key steps precisely, in contrast to existing anti-inflammator
zheimer's. The discovery is critical, Dr. Bin Zhang explained, a co-author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. "We can now evaluate drugs that impact the TREM2- TYROBP pathway as potential therapies... and design more specific compounds that target these key
atical model, a unified map of not only the prevailing genes present in late Alzheimer's but the various pathways that they trigger. One such gene, TYROBP, not typically connected to Alzheimer's but linked to brain inflammation, was shown to interact with TREM2, a gene recently connected to Alzheimer's
imers. The discovery is critical, explains Dr. Bin Zhang, a co-lead author of the study and Associate Professor of Genetics and Genomic Sciences at Mount Sinai. Because we can now "evaluate drugs that impact the TREM2-TYROBP pathway as potential therapies... and design more specific compounds that target th
atical model, a unified map of not only the prevailing genes present in late Alzheimer's but the various pathways that they trigger. One such gene, TYROBP, not typically connected to Alzheimer's but linked to brain inflammation, was shown to interact with TREM2, a gene recently connected to Alzheimer's
Entities connected to both Mount Sinai and TYROBP

Jeffrey Epstein
PERSON
Mount Sinai Hospital
ORGANIZATIONMerck Research Laboratories
ORGANIZATIONGenomic Sciences
ORGANIZATIONBin Zhang
PERSONthe Trilateral Commission
ORGANIZATIONSage Bionetworks
PERSON
Genetics
ORGANIZATIONthe Council on Foreign Relations
ORGANIZATIONthe Institute for Advanced Study
ORGANIZATIONthe Program for Evolutionary Dynamics
ORGANIZATIONSystems Medicine
ORGANIZATIONTrustee of the Institute of International Education Inc.
ORGANIZATIONQuantum Gravity Program
ORGANIZATIONThe Edge Organizatin Inc.
ORGANIZATIONthe Mind, Brain & Behavior Advisory Committee
ORGANIZATIONthe University of Pennsylvania
ORGANIZATIONthe Santa Fe Institute
ORGANIZATION
Santa Fe Institute
ORGANIZATIONAlzheimers
ORGANIZATION